This Immersive Enhanced Reality experience explores the rationale behind using disease-modifying therapies (DMTs) to delay the progression of type 1 diabetes (T1D), along with key considerations for applying these therapies in patient care. The activity will provide an overview of the criteria for identifying eligible patients who may benefit from these therapies, as well as important considerations for dosing and administration strategies. The goal is to support the integration of DMTs into care plans to delay T1D progression and optimize treatment outcomes.